WallStreetZenWallStreetZen

NASDAQ: EQ
Equillium Inc Stock Forecast, Predictions & Price Target

Analyst price target for EQ

Based on 1 analyst offering 12 month price targets for Equillium Inc.
Min Forecast
$5.00+249.65%
Avg Forecast
$5.00+249.65%
Max Forecast
$5.00+249.65%

Should I buy or sell EQ stock?

Based on 1 analyst offering ratings for Equillium Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EQ stock forecasts and price targets.

EQ stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-17

1 of 1

Forecast return on equity

Is EQ forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
28.09%

Forecast return on assets

Is EQ forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

EQ revenue forecast

What is EQ's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$41.1M+8.44%
Avg 2 year Forecast
$70.0M+84.73%
Avg 3 year Forecast
$31.4M-17.14%
EQ's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EQ revenue growth forecast

How is EQ forecast to perform vs Biotechnology companies and vs the US market?
Company
5.15%
Industry
36.33%
Market
10.01%
EQ's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EQ's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EQ vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EQ$1.43$5.00+249.65%Buy
ALGS$0.66N/AN/A
CTCX$2.50N/AN/A
OCEA$1.55N/AN/A
NTRB$4.87N/AN/A

Equillium Stock Forecast FAQ

Is Equillium Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: EQ) stock is to Buy EQ stock.

Out of 1 analyst, 0 (0%) are recommending EQ as a Strong Buy, 1 (100%) are recommending EQ as a Buy, 0 (0%) are recommending EQ as a Hold, 0 (0%) are recommending EQ as a Sell, and 0 (0%) are recommending EQ as a Strong Sell.

If you're new to stock investing, here's how to buy Equillium stock.

What is EQ's revenue growth forecast for 2024-2026?

(NASDAQ: EQ) Equillium's forecast annual revenue growth rate of 5.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.01%.

Equillium's revenue in 2024 is $37,894,000.On average, 3 Wall Street analysts forecast EQ's revenue for 2024 to be $1,448,723,524, with the lowest EQ revenue forecast at $377,225,846, and the highest EQ revenue forecast at $1,995,066,416. On average, 1 Wall Street analysts forecast EQ's revenue for 2025 to be $2,467,832,640, with the lowest EQ revenue forecast at $2,467,832,640, and the highest EQ revenue forecast at $2,467,832,640.

In 2026, EQ is forecast to generate $1,106,999,213 in revenue, with the lowest revenue forecast at $1,106,999,213 and the highest revenue forecast at $1,106,999,213.

What is EQ's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: EQ) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is EQ's Price Target?

According to 1 Wall Street analyst that have issued a 1 year EQ price target, the average EQ price target is $5.00, with the highest EQ stock price forecast at $5.00 and the lowest EQ stock price forecast at $5.00.

The Wall Street analyst predicted that Equillium's share price could reach $5.00 by May 17, 2025. The average Equillium stock price prediction forecasts a potential upside of 249.65% from the current EQ share price of $1.43.

What is EQ's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: EQ) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.